Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard Sells 2,000 Shares of Stock

Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard sold 2,000 shares of the stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $8.37, for a total transaction of $16,740.00. Following the transaction, the chief executive officer now directly owns 14,605,662 shares of the company’s stock, valued at $122,249,390.94. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Thomas Sandgaard also recently made the following trade(s):

• On Monday, November 11th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $9.09, for a total value of $18,180.00.
• On Friday, November 8th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.77, for a total value of $17,540.00.
• On Wednesday, November 6th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.82, for a total value of $17,640.00.
• On Monday, November 4th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.67, for a total transaction of $17,340.00.
• On Friday, November 1st, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.63, for a total transaction of $17,260.00.
• On Wednesday, October 30th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.92, for a total transaction of $17,840.00.

Zynex Stock Down 5.1 %

Shares of Zynex stock opened at $8.13 on Thursday. The company has a quick ratio of 3.15, a current ratio of 3.94 and a debt-to-equity ratio of 1.66. Zynex, Inc. has a 52-week low of $7.15 and a 52-week high of $13.77. The company has a market capitalization of $258.94 million, a P/E ratio of 54.20 and a beta of 0.53. The company has a 50 day moving average of $8.22 and a 200 day moving average of $8.92.

Zynex (NASDAQ:ZYXI) last released its quarterly earnings data on Thursday, October 24th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.01. The business had revenue of $49.97 million during the quarter, compared to analysts’ expectations of $50.83 million. Zynex had a net margin of 2.49% and a return on equity of 13.05%. The company’s revenue for the quarter was up .1% on a year-over-year basis. During the same period in the previous year, the company earned $0.10 EPS. As a group, research analysts forecast that Zynex, Inc. will post 0.2 EPS for the current fiscal year.

Institutional Investors Weigh In On Zynex

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Gladius Capital Management LP increased its stake in Zynex by 53.4% in the third quarter. Gladius Capital Management LP now owns 5,002 shares of the company’s stock valued at $41,000 after purchasing an additional 1,742 shares during the last quarter. State Board of Administration of Florida Retirement System purchased a new position in shares of Zynex in the 1st quarter valued at $137,000. Investment Partners Asset Management Inc. acquired a new stake in Zynex during the 3rd quarter worth $96,000. Hsbc Holdings PLC acquired a new stake in Zynex during the 2nd quarter worth $113,000. Finally, Quest Partners LLC lifted its position in Zynex by 646.7% in the second quarter. Quest Partners LLC now owns 12,926 shares of the company’s stock valued at $120,000 after acquiring an additional 11,195 shares during the last quarter. Institutional investors and hedge funds own 29.68% of the company’s stock.

Analyst Upgrades and Downgrades

ZYXI has been the subject of several research reports. HC Wainwright boosted their price target on shares of Zynex from $16.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, October 25th. Royal Bank of Canada lowered their target price on Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.